Group 1 - TimesSquare Capital Management's "U.S. Small Cap Growth Strategy" reported a gross return of 2.26% and a net return of 2.01% for Q3 2025, significantly underperforming the Russell 2000 Growth Index, which returned 12.19% [1] - All asset classes except fixed income outside the U.S. posted positive returns during the quarter [1] - The fund's top five holdings were highlighted as its best picks for 2025 [1] Group 2 - Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) was noted for a one-month return of 15.54% and a 52-week gain of 79.65%, with a market capitalization of $3.905 billion as of January 5, 2026 [2] - Mirum Pharmaceuticals reported revenue of $133 million in Q3 2025, reflecting a nearly 50% year-over-year increase [3] - The company is developing new applications for its flagship treatment, Livmarli, to address a third indication [3]

Market Predictions for 2026 - The S&P 500 is expected to deliver single-digit gains in 2026, ending a streak of double-digit gains over the past three years, but no major market sell-off is anticipated due to strong economic and corporate earnings [4][5] - Small- and mid-cap stocks are predicted to outperform larger stocks, with Mirum Pharmaceuticals highlighted as a potential winner after its share price nearly doubled in 2025, and expected positive results from clinical studies in 2026 [6][7][8] - The AI sector is expected to shift from hype to tangible returns, with Alphabet predicted to continue benefiting from its Google Cloud unit and agentic AI technology, which is anticipated to drive growth [9][10][12] - The renewable energy sector is expected to continue its rebound, driven by strong AI growth and increased demand for energy to power data centers, with Brookfield Renewable and Clearway Energy expected to perform well [13][15] - Political dynamics in the mid-term election year are expected to create volatility in the stock market, but once the uncertainty fades, stocks are predicted to move higher, with potential winners in the cannabis industry if Democrats gain control [16][18]

Core Viewpoint - Newsmax, despite having over 50 million regular viewers in the U.S., faces significant competition and challenges in the market, particularly from larger players like Fox Corp, and is predicted to underperform compared to other stocks in the next five years [1][2]. Group 1: Newsmax Overview - Newsmax has a market capitalization of approximately $1.1 billion and has recently expanded into Europe and the Middle East, which may increase its audience [1][2]. - The company reported a net loss of $4.1 million in the third quarter of 2025, indicating ongoing profitability challenges [7]. Group 2: Competitor Analysis - Fox Corp - Fox Corp, Newsmax's largest competitor, has a market cap of nearly $31 billion, significantly larger than Newsmax's [4]. - In the latest quarter, Fox reported a profit of $690 million, while Newsmax's revenue growth is in low single-digit percentages [7]. - Fox's shares have a price-to-sales ratio of 1.8, which is more attractive compared to Newsmax's forward sales multiple of 6 [7]. Group 3: Competitor Analysis - Mirum Pharmaceuticals - Mirum Pharmaceuticals has a market cap of around $4 billion and reported a revenue increase of 47% year-over-year in the third quarter, driven by its liver disease drug Livmarli [8][9]. - The company is optimistic about its pipeline, including potential blockbuster drugs and plans to acquire Bluejay Therapeutics, which could enhance its portfolio [11][12]. Group 4: Competitor Analysis - The Trade Desk - The Trade Desk, a leading advertising technology company, has a market cap of $19 billion and is expected to outperform Newsmax in the long term [13][15]. - The Trade Desk's growth opportunities are bolstered by the rise of ad-supported connected TV and international market expansion [15].

Core Insights - Mirum is a biopharmaceutical company focused on therapies for rare and orphan diseases, particularly liver disorders, leveraging its drug development expertise to meet significant unmet medical needs [1] - The company has seen a substantial increase in its stock price, with shares priced at $79.26, reflecting an 89% increase over the past year, significantly outperforming the S&P 500's 15% rise [2] Financial Performance - Mirum reported third-quarter revenue of $133 million, representing a 47% increase year-over-year, and raised its full-year revenue guidance to between $500 million and $510 million, driven by strong sales of LIVMARLI and expanding bile acid medicine revenue [6] - The company's cash and investments reached $378 million by the end of the quarter, providing financial flexibility to support multiple pipeline developments without immediate dilution concerns [6] Shareholder Activity - Eventide Asset Management sold 114,922 shares of Mirum, reducing its stake but increasing the net position value by approximately $50.70 million due to the stock price surge [3][4] - Despite the sale, Mirum became the second-largest equity holding in Eventide's portfolio, indicating a strategic decision to maintain a significant position in a company with strong growth potential [5] Market Position - Mirum's focus on rare disease markets provides a competitive advantage by targeting high-value, underserved patient populations, which is critical for driving growth through proprietary product commercialization [1]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX. ...

Core Insights - Mirum Pharmaceuticals' revenue is primarily driven by its lead product, Livmarli, which has shown consistent sales growth since its launch [1][3][11] Product Overview - Livmarli is an orally administered IBAT inhibitor approved for treating cholestatic pruritus in patients with Alagille syndrome and certain patients with PFIC in the U.S. and Europe [2] - A new tablet formulation of Livmarli has been approved, enhancing convenience for older patients [3] Financial Performance - In the first nine months of 2025, Livmarli's net product sales reached $253.6 million, reflecting a 70% year-over-year increase [3] - Mirum anticipates total revenues for 2025 to be between $500 million and $510 million, up from a previous estimate of $490 million to $510 million, driven by Livmarli and bile acid products [6] Product Portfolio Expansion - Mirum has made progress with other marketed products, Cholbam and Ctexli, which were added to its portfolio following the acquisition of Travere Therapeutics' bile acid products in 2023 [5][6] Pipeline Developments - Mirum's lead pipeline candidate, volixibat, is currently under evaluation in two phase IIb studies for primary biliary cholangitis and primary sclerosing cholangitis [7] Competitive Landscape - Mirum faces competition from Albireo AB's Bylvay, which directly competes with Livmarli in the PFIC and ALGS markets [9] - GSK is developing linerixibat, another IBAT inhibitor, which could pose significant competition for Mirum's pipeline candidate volixibat [10][12] Stock Performance and Valuation - Over the past six months, Mirum's shares have increased by 35.9%, outperforming the industry and the S&P 500 [13] - The company's shares are trading at a premium, with a price/book ratio of 11.87 compared to the industry average of 3.55 [14] Earnings Estimates - The Zacks Consensus Estimate for Mirum's 2025 loss per share has narrowed from 67 cents to 41 cents, while estimates for 2026 have shifted from earnings of 4 cents per share to a loss of 29 cents [15]

Core Insights - Mirum Pharmaceuticals is focused on developing therapies for rare liver diseases and is expanding its team through inducement grants to attract key talent [1] - Raymond James has given MIRM a "Strong Buy" rating with a price target of $110, indicating a potential increase of approximately 68.92% from its stock price of $64.67 [2] - The company currently has a negative earnings yield of -1.26% and a negative price-to-earnings (P/E) ratio of -79.19, indicating a lack of profitability [3] Financial Metrics - The price-to-sales ratio is 6.78, and the enterprise value to sales ratio is 6.85, suggesting investors are willing to pay a premium for revenue [3] - The enterprise value to operating cash flow ratio is high at 72.31, indicating potential overvaluation relative to cash flow [3] - The debt-to-equity ratio stands at 1.08, showing a moderate level of debt compared to equity, while the current ratio of 3.31 indicates strong liquidity [3]

Core Viewpoint - Mirum Pharmaceuticals Inc. is viewed positively by Wall Street analysts, with recent upgrades in price targets following its acquisition of Bluejay Therapeutics for $620 million, which enhances its position in the rare liver disease market [1][2][4]. Group 1: Acquisition Details - Mirum Pharmaceuticals has agreed to acquire Bluejay Therapeutics for $620 million in cash, gaining worldwide rights to brelovitug, a monoclonal antibody in development for chronic hepatitis D [2][3]. - The acquisition aligns with Mirum's strategy of advancing high-impact medicines for rare diseases, as stated by CEO Chris Peetz [3]. Group 2: Analyst Ratings and Projections - Baird has raised its price target for Mirum Pharmaceuticals from $80 to $88, maintaining an Outperform rating [1][2]. - Morgan Stanley has reiterated an Overweight rating with a price target of $81, viewing the acquisition as a strategic move that could lead to over $4 billion in peak sales from the enlarged pipeline [4]. Group 3: Company Focus - Mirum Pharmaceuticals specializes in developing treatments for rare and debilitating liver diseases, particularly those affecting children, with key products like LIVMARLI for cholestatic pruritus in Alagille syndrome and Progressive Familial Intrahepatic Cholestasis [5].